Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 12, 2024 -- For patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who experienced disease progression on first-line chemotherapy, fruquintinib (F) plus paclitaxel (PTX) improves progression free survival (PFS), according to a study presented during the February 2024 session of the American Society for Clinical Oncology Plenary Series.
Rui-Hua Xu, M.D., Ph.D., from the Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues examined the efficacy and safety of F+PTX (350 patients) versus PTX alone (349 patients) in patients with advanced G/GEJ adenocarcinoma who experienced disease progression on first-line chemotherapy containing fluoropyrimidine or platinum (the FRUTIGA trial).
The researchers observed a significant improvement in PFS with F+PTX versus placebo+PTX (median, 5.55 versus 2.73 months). In the F+PTX group, the overall response rate was significantly higher (42.5 versus 22.4 percent). Median overall survival was 9.63 and 8.41 months with F+PTX and placebo+PTX, respectively. In post-hoc analyses adjusting for subsequent antitumor therapies and baseline factors, there was a nominal statistically significant improvement observed in overall survival with F+PTX. Median PFS was even more prolonged among patients with lymph node metastases and nondiffuse G/GEJ adenocarcinoma (6.08 versus 2.69 months); overall survival also showed a nominal statistically significant improvement (9.56 versus 7.85 months).
"Fruquintinib plus paclitaxel could be a promising second-line treatment option for patients with advanced gastric/gastroesophageal adenocarcinoma that progressed on first-line chemotherapy," Xu said in a statement.
The FRUTIGA trial was funded by HUTCHMED.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
H. Pylori Testing Feasible for People in Community Settings
THURSDAY, April 18, 2024 -- Community Helicobacter pylori (HP) testing in high-risk individuals is technically feasible, according to a study published online April 3...
AACR: Cadonilimab Plus Chemo Beneficial for Gastric Adenocarcinoma
MONDAY, April 8, 2024 -- For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and...
Consumption of Ultra-Processed Foods Tied to Upper Digestive Tract Cancers
FRIDAY, Dec. 22, 2023 -- Higher ultra-processed food (UPF) consumption is associated with a greater risk for head and neck cancer (HNC) and esophageal adenocarcinoma (OAC)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.